Cytori Therapeutics Inc. (CYTX) Stock Price Down 3.2%
Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) dropped 3.2% during trading on Wednesday . The stock traded as low as $2.11 and last traded at $2.14, with a volume of 99,238 shares changing hands. The stock had previously closed at $2.21.
CYTX has been the subject of several research reports. Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of Cytori Therapeutics in a research report on Wednesday, July 20th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Tuesday, July 12th. Finally, Roth Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Cytori Therapeutics in a research report on Tuesday, June 28th.
The stock’s market capitalization is $44.59 million. The company has a 50-day moving average price of $2.06 and a 200 day moving average price of $2.77.
Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, August 4th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.04. During the same period last year, the firm earned ($0.06) EPS. The company earned $1.10 million during the quarter, compared to analyst estimates of $2.50 million. The company’s quarterly revenue was down 31.3% compared to the same quarter last year. Analysts expect that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current year.
Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.